Lee, Jae-Lyun
154  Ergebnisse:
Personensuche X
?
2

FORT-1:Phase II/III study of rogaratinib versus chemotherap..:

Sternberg, Cora N ; Petrylak, Daniel P ; Bellmunt, Joaquim...
Sternberg , C N , Petrylak , D P , Bellmunt , J , Nishiyama , H , Necchi , A , Gurney , H , Lee , J-L , Van Der Heijden , M S , Rosenbaum , E , Penel , N , Pang , S-T , Li , J-R , García Del Muro , X , Joly , F , Pápai , Z , Bao , W , Ellinghaus , P , Lu , C , Sierecki , M , Coppieters , S , Nakajima , K , Ishida , T C & Quinn , D I 2023 , ' FORT-1 : Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1 / 3 mRNA expression ' , Journal of Clinical Oncology , vol. 41 , no. 3 , pp. 629-639 . https://doi.org/10.1200/JCO.21.02303.  , 2023
 
?
5

Avelumab first-line maintenance plus best supportive care (..:

Lee, Jae-Lyun ; Desai, Chirag ; Park, Se Hoon...
Lee , J-L , Desai , C , Park , S H , Tsuchiya , N , Su , P J , Chan , T T W , Gurney , H , Gao , S , Wang , J , Sandner , R , di Pietro , A & Eto , M 2023 , ' Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma : JAVELIN Bladder 100 Asian subgroup analysis ' , Urologic Oncology: Seminars and Original Investigations , vol. 41 , no. 5 , pp. 256.e17-256.e25 . https://doi.org/10.1016/j.urolonc.2023.02.002.  , 2023
 
?
7

Clinical evidence and insights supporting the use of avelum..:

Eto, Masatoshi ; Lee, Jae-Lyun ; Chang, Yen-Hwa...
Eto , M , Lee , J-L , Chang , Y-H , Gao , S , Singh , M & Gurney , H 2022 , ' Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region ' , Asia-Pacific Journal of Clinical Oncology , vol. 18 , no. 5 , pp. e191-e203 . https://doi.org/10.1111/ajco.13765.  , 2022
 
?
 
?
 
?
10

FORT-1: Phase II/III Study of Rogaratinib Versus Chemothera..:

Sternberg, Cora N ; Petrylak, Daniel P ; Bellmunt, Joaquim...
Reproducció del document publicat a: https://doi.org/10.1200/JCO.21.02303.  , 2022
 
?
 
?
13

Putative biomarkers of clinical benefit with pembrolizumab ..:

Bellmunt, Joaquim ; de Wit, Ronald ; Fradet, Yves...
Bellmunt , J , de Wit , R , Fradet , Y , Climent , M A , Petrylak , D P , Lee , J-L , Fong , L , Necchi , A , Sternberg , C N , O'Donnell , P H , Powles , T , Plimack , E R , Bajorin , D F , Balar , A V , Castellano , D , Choueiri , T K , Culine , S , Gerritsen , W , Gurney , H , Quinn , D I , Vuky , J , Vogelzang , N J , Cristescu , R , Lunceford , J , Saadatpour , A , Loboda , A , Ma , J , Rajasagi , M , Godwin , J L , Moreno , B H & Grivas , P 2022 , ' Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer : results from the KEYNOTE-045 and KEYNOTE-052 landmark trials ' , Clinical Cancer Research , vol. 28 , no. 10 , pp. 2050-2060 . https://doi.org/10.1158/1078-0432.CCR-21-3089.  , 2022
 
?
14

Two-year adjuvant imatinib mesylate after complete resectio..:

Kang, Yoon-Koo ; Kang, Byung Woog ; Im, Seock-Ah...
Cancer Chemotherapy and Pharmacology, Vol.71 No.2, pp.551-552.  , 2022
 
?
 
1-15